Literature DB >> 503223

Induction and kinetics of natural killer cells in humans following interferon therapy.

J R Huddlestone, T C Merigan, M B Oldstone.   

Abstract

Natural killer (NK) cells are non-B, non-T lymphocytes that effect spontaneous cytolysis of both virus-infected and neoplastically transformed target cells. These NK lymphocytes have been detected in several species including man. Interferon is a primary regulator of natural killer activity. Because NK cells have been implicated in the regulation of tumour cell expression and can be induced by interferon in murine models, we have studied patients receiving large doses of interferon to determine (1) whether interferon could induce NK lymphocytes in the peripheral blood of man, and (2) whether there are characteristic kinetics for the appearance, disappearance and reactivation of NK lymphocytes following interferon therapy. We report here the activation of human NK cells by the systemic inoculation of human subjects with interferon. Five patients received interferon as therapy for non-Hodgkin's lymphoma. All showed a marked increase in NK cell activity 12--24 h after inoculation. Peak NK activity occurred 18 h after introducing interferon, and thereafter declined rapidly but remained above pre-interferon levels. Induced NK activity occurred with reintroduction of interferon but at lower levels of activity and with different kinetics.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 503223     DOI: 10.1038/282417a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  33 in total

1.  Cytotoxicity of human peripheral blood T-lymphocyte clones activated by hepatitis B virus surface antigen.

Authors:  A A Hakim
Journal:  Experientia       Date:  1985-12-15

2.  Effect of recombinant gamma interferon on natural killer cell activity in patients with gastric cancer.

Authors:  Y Kuwahara; K Kusugami; K Morise; K Shimokata
Journal:  Gastroenterol Jpn       Date:  1987-08

Review 3.  Natural killer activity: early days, advances, and seminal observations.

Authors:  John R Ortaldo; Robert H Wiltrout; Craig W Reynolds
Journal:  Crit Rev Oncog       Date:  2014

4.  Effect of retinoids on natural killer cell activity.

Authors:  P D Pigatto; L Bersani; F Colotta; M Morelli; G F Altomare; M M Polenghi
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

5.  Increase of predominantly k-type light chains in the CSF of a case of subacute sclerosing panencephalitis treated with interferon.

Authors:  P Annunziata; A Battista; G C Guazzi
Journal:  Ital J Neurol Sci       Date:  1985-06

Review 6.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

7.  Clinical effect of interferon in malignant brain tumours.

Authors:  M Nagai; T Arai
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

8.  Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.

Authors:  G T Budd; R M Bukowski; L Miketo; B Yen-Lieberman; M R Proffitt
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Natural cell-mediated cytotoxicity of bovine mononuclear cells against virus-infected cells.

Authors:  M Campos; C R Rossi; M J Lawman
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

10.  Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).

Authors:  A M Eggermont; W Weimar; B Tank; A M Dekkers-Bijma; R L Marquet; J S Lameris; D L Westbroek; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.